Associated Papers
Genomic landscape of hormone therapy-resistant HR-positive, HER2-negative breast cancer.
Chaubal R et al.
Breast Cancer Research and Treatment, 2025
40652157 (PubMed )
Supplement: 10549_2025_7759_MOESM2_ESM.xlsx › stable7
Interface-guided phenotyping of coding variants in the transcription factor RUNX1.
Ozturk K et al.
Cell Reports, 2024
38968069 (PubMed )
Supplement: NIHMS2011877-supplement-8.xlsx › Sheet1
SmMIP-tools: a computational toolset for processing and analysis of single-molecule molecular inversion probes-derived data.
Medeiros JJF et al.
Bioinformatics (oxford, England), 2022
35150236 (PubMed )
Supplement: btac081_supplementary_data.zip › Table_S6.xlsx › High_Confidence_SNVs
Myeloid malignancies with translocation t(4;12)(q11-13;p13): molecular landscape, clonal hierarchy and clinical outcomes.
Parinet V et al.
Journal of Cellular and Molecular Medicine, 2021
34492730 (PubMed )
Supplement: JCMM-25-9557-s001.xlsx › S3._mutations_list
Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription.
Maicas M et al.
Oncogene, 2013
RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation.
Kuo MC et al.
Leukemia, 2009
Select a paper to view details